HRP20100208T8 - Postupak liječenja akutnog rinosinusitisa - Google Patents

Postupak liječenja akutnog rinosinusitisa

Info

Publication number
HRP20100208T8
HRP20100208T8 HR20100208T HRP20100208T HRP20100208T8 HR P20100208 T8 HRP20100208 T8 HR P20100208T8 HR 20100208 T HR20100208 T HR 20100208T HR P20100208 T HRP20100208 T HR P20100208T HR P20100208 T8 HRP20100208 T8 HR P20100208T8
Authority
HR
Croatia
Prior art keywords
treatment
procedure
acute rhinosinusitis
disease
mometasone furoate
Prior art date
Application number
HR20100208T
Other languages
English (en)
Croatian (hr)
Inventor
Bloom Melvyn
Danzig Melvyn
Rohane Patricia
Staudinger Heribert
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34825945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100208(T8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of HRP20100208T1 publication Critical patent/HRP20100208T1/hr
Publication of HRP20100208T8 publication Critical patent/HRP20100208T8/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
HR20100208T 2004-01-21 2005-01-19 Postupak liječenja akutnog rinosinusitisa HRP20100208T8 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53783004P 2004-01-21 2004-01-21
PCT/US2005/002105 WO2005072704A2 (en) 2004-01-21 2005-01-19 Method of treating acute rhinosinusitis

Publications (2)

Publication Number Publication Date
HRP20100208T1 HRP20100208T1 (hr) 2010-05-31
HRP20100208T8 true HRP20100208T8 (hr) 2010-06-30

Family

ID=34825945

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100208T HRP20100208T8 (hr) 2004-01-21 2005-01-19 Postupak liječenja akutnog rinosinusitisa

Country Status (16)

Country Link
US (2) US20050186144A1 (https=)
EP (2) EP1711164B1 (https=)
JP (2) JP4976139B2 (https=)
AT (1) ATE461693T1 (https=)
CA (1) CA2554064A1 (https=)
CY (1) CY1110620T1 (https=)
DE (1) DE602005020113D1 (https=)
DK (1) DK1711164T3 (https=)
ES (2) ES2340777T3 (https=)
HR (1) HRP20100208T8 (https=)
MX (1) MXPA06008240A (https=)
PL (1) PL1711164T3 (https=)
PT (1) PT1711164E (https=)
RS (1) RS51335B (https=)
SI (1) SI1711164T1 (https=)
WO (1) WO2005072704A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005020113D1 (de) * 2004-01-21 2010-05-06 Schering Corp Verfahren zur behandlung von akuten rhinosinusitis
US20090325917A1 (en) * 2006-10-19 2009-12-31 Cipla Limited Pharmaceutical Compositions and Nasal Spray Incorporating Anhydrous Mometasone Furoate
RU2407558C1 (ru) * 2009-07-02 2010-12-27 Федеральное государственное учреждение "Российский научный центр восстановительной медицины и курортологии Федерального агентства по здравоохранению и социальному развитию РФ" (ФГУ "РНЦВМиК Росздрава") Способ лечения острого риносинусита у детей
TWI411121B (zh) * 2010-03-11 2013-10-01 Ind Tech Res Inst 光吸收層之製造方法及應用其之太陽能電池結構
WO2014106021A1 (en) 2012-12-27 2014-07-03 Massachusetts Eye & Ear Infirmary Treatment of rhinosinusitis with p-glycoprotein inhibitors
WO2017123933A1 (en) 2016-01-15 2017-07-20 Massachusetts Eye And Ear Infirmary Secreted p-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis
US12295933B2 (en) 2019-03-25 2025-05-13 Massachusetts Eye And Ear Infirmary Methods and compositions to treat and diagnose diseases or pathologies associated with inflammation of the sinuses and nasal cavity
IL299210A (en) * 2020-06-21 2023-02-01 Massachusetts Eye & Ear Infirmary Combined treatment of verapamil and methotrexate for the treatment of chronic rhinosinusitis
JP2024049405A (ja) * 2021-02-22 2024-04-10 興和株式会社 新規吸入剤
EP4566595A1 (en) * 2023-12-07 2025-06-11 Bernhard Roth Combination preparation for the treatment of acute and chronic rhinosinusitis

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE8790T1 (de) 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
US4731447A (en) * 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4873335A (en) * 1986-03-12 1989-10-10 Schering Corporation 3-phenethyl-2-benzene-amides or aza-derivatives thereof
ZA924164B (en) 1991-06-10 1993-02-24 Schering Corp Non-chlorofluorocarbon aerosol formulations
HUT67445A (en) * 1991-06-10 1995-04-28 Schering Corp Aerosol formulations containing 1,1,1,2-tetrafluorethane
US6127353A (en) * 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US6068832A (en) 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
US5837713A (en) * 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6187765B1 (en) 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
US6297227B1 (en) * 1998-09-10 2001-10-02 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
SE9803770D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Dry powder pharmaceutical formulation
US6465581B1 (en) * 2001-01-24 2002-10-15 The Goodyear Tire & Rubber Company Silica reinforced rubber composition which contains stabilized unsymmetrical coupling agents and article of manufacture, including a tire, having at least one component comprised of such rubber composition
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
WO2004018025A1 (en) * 2002-08-23 2004-03-04 Schering Corporation Pharmaceutical compositions
US20040081625A1 (en) * 2002-10-21 2004-04-29 Schering Corporation Nasal formulations for the treatment of allergies
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
KR20060106823A (ko) * 2003-10-20 2006-10-12 쉐링 코포레이션 약제학적 에어로졸 조성물
DE602005020113D1 (de) * 2004-01-21 2010-05-06 Schering Corp Verfahren zur behandlung von akuten rhinosinusitis
CN103429296A (zh) 2010-12-13 2013-12-04 内诺斯蒂姆股份有限公司 递送导管系统和方法
US9106249B1 (en) 2014-09-04 2015-08-11 Semtech Corporation Calibration of a time-interleaved analog-to-digital converter

Also Published As

Publication number Publication date
EP2201936B1 (en) 2013-06-19
DK1711164T3 (da) 2010-07-19
US20050186144A1 (en) 2005-08-25
SI1711164T1 (sl) 2010-06-30
JP4976139B2 (ja) 2012-07-18
JP2008110991A (ja) 2008-05-15
US20090022671A1 (en) 2009-01-22
DE602005020113D1 (de) 2010-05-06
PL1711164T3 (pl) 2010-09-30
ATE461693T1 (de) 2010-04-15
ES2426957T3 (es) 2013-10-28
EP2201936A1 (en) 2010-06-30
WO2005072704A3 (en) 2006-07-20
RS51335B (sr) 2011-02-28
ES2340777T3 (es) 2010-06-09
MXPA06008240A (es) 2006-08-31
WO2005072704A2 (en) 2005-08-11
PT1711164E (pt) 2010-06-28
CY1110620T1 (el) 2015-04-29
HRP20100208T1 (hr) 2010-05-31
CA2554064A1 (en) 2005-08-11
EP1711164A2 (en) 2006-10-18
EP1711164B1 (en) 2010-03-24
JP2007518817A (ja) 2007-07-12

Similar Documents

Publication Publication Date Title
BRPI0518266A2 (pt) medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
DE60120936D1 (de) Behandlung von atemerkrankungen
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
AR071187A1 (es) Compuesto de arilmetil-tiazinamina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento de la enfermedad de alzheimer
BR0309670A (pt) Compostos derivados dicetohidrazina e drogas contendo os compostos como o ingrediente ativo
ATE543489T1 (de) Orale dosierformen mit progesteron und verwendungs- und herstellungsverfahren dafür
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
MY159377A (en) Aqueous suspensions of ciclesonide for nebulisation
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
ATE543804T1 (de) Neue verbindungen
WO2008116890A3 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
HRP20100208T8 (hr) Postupak liječenja akutnog rinosinusitisa
MEP42908A (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds
BR0208027A (pt) Composto de n-fenilarilsulfonamida, droga contendo o composto como ingrediente ativo, intermediário para o composto, e processos para a produção do mesmo
EA201170108A1 (ru) Сосательная композиция для лечения воспалительных заболеваний полости рта и глотки
EA200600854A1 (ru) Новые соли тиотропия, способ их получения, а также содержащие их лекарственные композиции
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
JP2019529569A5 (https=)
IL201491A (en) Aryl Sulfonamide Amino Alkoxy Compounds, Preparation Process, and Pharmaceutical Preparations Containing Them
NZ597657A (en) Use sulphur particles less than 300 microns and sodium lignin sulfonate for treating diseases casused by microbial pathogenic infections
RU2010120806A (ru) Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид
ATE399543T1 (de) Neue synergistische zusammensetzung enthaltend roflumilast und formoterol